Entdoc, not trying to compare efficacy but rather the trials and tribulations of a small bio taking a pioneering platform forward for FDA approval. The move you describe with DNDN took place at an earlier time (2007) when the FDA did turn down approval. The time I'm referring to took place in I believe 2009/2010 just prior to the 2nd time DNDN sought approval.
A lot can be learned by a small bio by studying what went right/wrong with DNDN.
Do you think BAVI in combination with the infused antigens (Provenge) could lead to better efficacy in prostate cancer?
News 
Market Data 
Discover 
AI
